Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq

Why It Matters

The SPAC route supplies crucial funding for early‑stage regenerative‑medicine companies while keeping biotech listings active despite a slowdown in traditional IPOs, signaling strong investor interest in novel cell‑based therapies.

Key Takeaways

• PrimeGen valued at $1.5 billion via SPAC merger.
• DT Cloud Star raised $69 million IPO in July 2024.
• Funds target triple‑activated mesenchymal stem cell platform.
• No clinical data yet; FDA IND meeting completed.
• SPACs revive biotech listings amid IPO slowdown.

Pulse Analysis

The biotech sector has turned increasingly to special‑purpose acquisition companies as a shortcut to public markets. After a sharp decline in traditional IPO activity in 2025, SPACs kept the Nasdaq pipeline alive, with at least five deals recorded last year. DT Cloud Star Acquisition Corp., which raised $69 million in its July 2024 IPO, is one of the newer blank‑check vehicles targeting high‑growth life‑science targets. By merging with a SPAC, companies can secure capital faster and sidestep the lengthy underwriting process that often stalls early‑stage innovators.

PrimeGen US, a California‑based stem‑cell specialist, will join the 2026 Nasdaq cohort through a merger that values the firm at roughly $1.5 billion in equity. The capital infusion is earmarked for its triple‑activated mesenchymal stem cell pipeline, a platform designed to treat acute liver injury and related complications such as alcohol‑induced hepatitis. While preclinical animal studies have shown promise, the company has not yet entered human trials; it completed a pre‑IND meeting with the FDA in December and now seeks IND clearance. The SPAC proceeds will fund the IND filing and subsequent Phase 1 studies.

The deal underscores investors’ appetite for regenerative‑medicine assets despite the inherent clinical uncertainty. If PrimeGen can translate its preclinical results into safe, effective therapies, it could capture a sizable share of the emerging liver‑failure market, estimated at several billion dollars annually. However, the company’s cautionary disclaimer—highlighting no guarantee of FDA approval or trial success—reminds stakeholders of the high‑risk nature of early‑stage biotech. Successful execution would not only validate the SPAC model for similar ventures but also accelerate the delivery of novel cell‑based treatments to patients in need.